Short Bowel Syndrome — A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB
Citation(s)
A 90 Day, Phase 3, Open Labeled Exploratory Study of RELiZORB to Evaluate Safety, Tolerability, and Nutrient Absorption in Children With Short Bowel Syndrome Who Are Dependent on Parenteral Nutrition